Lead Sponsor

Novartis Pharmaceuticals

Age

6 - 21 years

Sex

ALL

Healthy Volunteers

No

•Completed all visits in study CTBM100C2303 and CTBM100C2303E1, and visit 11 of study CTBM100C2303E1 took place not more than 5 days before enrollment into this study.
•Confirmed diagnosis of cystic fibrosis participants with P. aeruginosa infection.
•Forced Expiratory Volume in one second (FEV1) at screening (at start of study CTBM100C2303) must be between 25% and 80% of normal predicted values.

•Any use of inhaled anti-pseudomonal antibiotics between the termination of the trial CTMB100C2303E1 and the enrollment into this study.
•Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.